Co-organizing with the Chinese Evidence-based Medicine Center, the ISPOR West China Chapter hosted the first National Forum on Real World Evidence (RWE) and Healthcare Decision Making on July 7-9, 2017 in Chengdu, China. This is the first academic event in China on RWE. The supporting organizations included Wu JiePing Medical Foundation, West China Hospital, BMJ China, IDEAL China Center, Journal of Evidence-based Medicine, and Chinese Journal of Evidence-based Medicine. The forum focused on four theme topics: 1) Global Perspective of Real World Evidence, 2) Real-World Research and Clinical Translation, 3) Real World Evidence and Drug and Devices Evaluation, and 4) Real World Data in China. There were over 300 participants across China with some high-profile attendees including Professor Dakui Ying, former Vice Minister of Health, Dr. Trish Groves, Deputy Editor of The British Medical Journal (The BMJ), Dr. Xinling Li, Section Director of the National Center for Drug Reevaluation Center of the China FDA, and Professor Kun Zhao, Director of the China National Health Development Research Center. Professor Xin Sun, the President of ISPOR West China Chapter made a speech on the initiative for Establishment of China Real World Studies Alliance (ChinaREAL), a nationwide consortium of researchers and users of real world evidence. The purposes of ChinaREAL are to bring together a group of research scientists, clinicians, and policy makers across the country and take the lead in pushing real world evidence movement forward in China under the directorship of Professor Sun.
At the opening ceremony of the Forum, Dr. Trish Groves, Deputy Editor of The BMJ presented the prestigious BMJ Award of Excellence to Professor Xin Sun and his CREAT team (Clinical Research, Evaluation, And Translation) to honor their outstanding achievements and significant contributions to the development of evidence-based medicine in China. Professor Sun is the most prolific author of The BMJ from China who published 9 articles over the past seven years. This is the first time for the BMJ to give this Award to a Chinese author, which indicates that Professor Sun and his CREAT team, and the Chinese Evidence-based Medicine Center are well-recognized by a top international journal of medicine.
New! The Chapter organized the Real World Study (RWS) Methodology Training Program on 3-4 December 2016 in Chengdu, China. The program was free to attendees and aimed to provide technical support for students and researchers who were interested in real world studies. This two-day training program contained three sessions: 1) Pragmatic Trials, 2) RWS Based on Medical Database, and 3) Systematic Reviews of Real World Evidence. Over 15 speakers from academic institutions and pharmaceutical industries were invited to present on a variety of topics related to real world studies. It attracted approximately 120 participants from 18 provinces around China.
New! The Chapter organized the 8th Asia Huaxia Pharmacoeconomics Forum titled ‘The Role of Pharmacoeconomics in Evidence-informed Health Policy Making’ on 28-29 May, 2016 in Chengdu, China. Topics covered included health system reform and pharmacoeconomics, evidence-informed health policy making and pharmacoeconomics, methods and applications of pharmacoeconomics, and health technology assessment. The Chinese speaking members from Chapters of ISPOR Singapore, Australia, Taiwan, Hong Kong, and five ISPOR Chapters in Mainland China were invited to attend the forum. Over 300 attendees from the academic institutions, pharmaceutical industries, health authorities, and other organizations participated in this event.
The Chapter organized the West China Forum on Drug and Medical Technology Assessment and Decision Making in November 2015. The forum included one plenary session and four panel sessions with over 20 seminars. The experts from academic institutions, clinical practice, pharmaceutical industries, and health authorities across China presented. The current status, challenges, and potential strategies of the assessment and policy making on post-marketing drugs and medical technology assessment have been deeply discussed and summarized. Participants gave positive and enthusiastic feedback and expressed interests in next forum.
|President||Xin Sun, PhD|
|President - Elect||Ting Xu, PhD|
|Director||Lingli Zhang, MD, PhD|
|Director||Ming Hu, PhD|
|Secretary||Jing Tan, PhD|